Free Trial

Eli Lilly and Company (LLY) Stock Price, News & Analysis

$918.00
+3.43 (+0.38%)
(As of 07/8/2024 ET)
Today's Range
$912.00
$928.61
50-Day Range
$734.97
$918.00
52-Week Range
$434.34
$928.60
Volume
2.34 million shs
Average Volume
2.61 million shs
Market Capitalization
$872.48 billion
P/E Ratio
135.20
Dividend Yield
0.57%
Price Target
$816.78

Eli Lilly and Company MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.84 Rating Score
Upside/​Downside
11.0% Downside
$816.78 Price Target
Short Interest
Healthy
0.76% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.63mentions of Eli Lilly and Company in the last 14 days
Based on 63 Articles This Week
Insider Trading
Selling Shares
$783.50 M Sold Last Quarter
Proj. Earnings Growth
40.12%
From $13.76 to $19.28 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.66 out of 5 stars

Medical Sector

114th out of 876 stocks

Pharmaceutical Preparations Industry

38th out of 416 stocks

LLY stock logo

About Eli Lilly and Company Stock (NYSE:LLY)

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

LLY Stock Price History

LLY Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 7/1 - 7/5 (LLY)
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.
syringes, pills, fat
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? (LLY)
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
Logo sign of Pharmaceutical Corporation Pfizer building
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes (LLY)
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.
Eli Lilly logo on smartphone screen with stock market background
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used off-label for weight loss.
Eli Lilly logo on smartphone screen with stock market background
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.
Eli Lilly and Company (NYSE:LLY) Shares Up 1.1%
Wall Street Lunch: Merger Monday In All Its Glory
Eli Lilly Buys Morphic for $3.2B
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2024
Ex-Dividend for 6/10 Dividend
5/15/2024
Dividend Payable
6/10/2024
Today
7/09/2024
Next Earnings (Confirmed)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
53245710
Employees
43,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$816.78
High Stock Price Target
$1,023.00
Low Stock Price Target
$535.00
Potential Upside/Downside
-11.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.84
Research Coverage
19 Analysts

Profitability

Net Income
$5.24 billion
Pretax Margin
21.04%

Debt

Sales & Book Value

Annual Sales
$35.93 billion
Cash Flow
$7.66 per share
Book Value
$11.44 per share

Miscellaneous

Free Float
949,169,000
Market Cap
$872.47 billion
Optionable
Optionable
Beta
0.41

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide, showcasing a strong commitment to innovation and growth in the healthcare sector.
  • The company offers a diverse range of pharmaceutical products, including insulin brands like Basaglar, Humalog, and Humulin, catering to a wide market and ensuring revenue stability.
  • Recent developments in Eli Lilly's product portfolio, such as the introduction of new insulin formulations like Humalog U-200 and Humalog Mix 50/50, demonstrate ongoing research and development efforts to meet evolving healthcare needs.
  • Investors may find the current stock price of Eli Lilly and Co attractive, providing a potentially lucrative investment opportunity based on market trends and financial performance.
  • Eli Lilly's strong global presence and established reputation in the pharmaceutical industry offer investors a sense of stability and reliability in their investment choices.

Cons

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • While Eli Lilly has a diverse product portfolio, the competitive nature of the pharmaceutical industry may pose challenges in maintaining market share and profitability over time.
  • Regulatory changes and healthcare policies can impact Eli Lilly's operations and financial performance, leading to uncertainties in the investment landscape.
  • Investors should consider the potential risks associated with investing in pharmaceutical companies, such as clinical trial failures, patent expirations, and market competition, which could affect Eli Lilly's stock value.
  • Fluctuations in global economic conditions and currency exchange rates may influence Eli Lilly's revenue streams and profitability, requiring investors to monitor external factors that could impact their investment returns.
  • While Eli Lilly has a history of innovation and product development, investors should be aware of the risks inherent in the pharmaceutical industry, including regulatory hurdles, pricing pressures, and market volatility that could affect the company's financial performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

LLY Stock Analysis - Frequently Asked Questions

How have LLY shares performed this year?

Eli Lilly and Company's stock was trading at $582.92 at the beginning of the year. Since then, LLY stock has increased by 57.5% and is now trading at $918.00.
View the best growth stocks for 2024 here
.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings data on Monday, May, 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm's revenue was up 26.0% compared to the same quarter last year.
Read the conference call transcript
.

What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?

399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

Does Eli Lilly and Company have any subsidiaries?

Eli Lilly and Company subsidiaries include Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and more.

Who are Eli Lilly and Company's major shareholders?

Top institutional investors of Eli Lilly and Company include DNB Asset Management AS (0.04%), Hudson Valley Investment Advisors Inc. ADV (0.01%), Trust Co. of Toledo NA OH and Partnership Wealth Management LLC. Insiders that own company stock include Lilly Endowment Inc, Jackson P Tai, Anne E White, Patrik Jonsson, Johna Norton, Alonzo Weems, Donald A Zakrowski, Acquisition Corp Kearny, Marschall S Runge and Ilya Yuffa.
View institutional ownership trends
.

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY) and Walt Disney (DIS).

This page (NYSE:LLY) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners